A review. Background: Severe acute respiratory syndrome coronavirus (SARS-CoV-2) is a novel virus that causes Coronavirus Disease 2019 (COVID-19). Whole genome sequencing (WGS) can be used to identify host genetic factors that may influence variability in symptom severity and outcomes among patients infected by SARS-CoV-2. However, WGS may incidentally reveal information about inherited predispositions to multiple diseases, including genetic variants/changes associated with current (undiagnosed) disease, drug response, and risk for future diseases. Addnl., serol. testing for SARS-CoV-2 antibodies is newly available to the public and can identify SARS-CoV-2 antibodies that are present in patients with either active disease or past infection. However, it cannot be used to identify immunity to COVID-19 at this time. The use of WGS and serol. testing in COVID-19 pos. patients poses challenges to Genetic Counselors (GC) and other healthcare professionals including: the communication of secondary findings to otherwise healthy individuals, the translation of serol. test results with presently uncertain health implications to patients, and barriers to healthcare delivery and counselling imposed by COVID-19 safety measures (e.g., restrictions to in-person appointments). Study design: Up to 1500 patients with a pos. COVID-19 nasopharyngeal, nasal or oral swab will be consented. Blood samples will be collected at baseline, 1 mo, 6 mo and 1 yr after diagnosis. Serial antibody (IgG, IgA, and IgM) titers, antigen target and viral neutralization will be assessed. DNA will be isolated from blood lymphocytes and the host genome will be sequenced. A novel workflow has been developed for patient intake, genetic counselling, return of secondary findings from WGS and serol. test results, as well as clinic referrals. After informed consent to participate is obtained, patients will complete an online intake questionnaire to collect information about their medical history and COVID-19 diagnosis. Patients will complete an online decision aid called the Genetics Adviser (currently in development), which will educate patients about the 5 categories of secondary findings they may choose to learn from WGS (clin. actionable genetic conditions, rare genetic conditions, common conditions/disease risks, carrier status, and drug reactions) before indicating their preferences for secondary findings in the online intake. Patients will also indicate whether or not they wish to learn their serol. SARS-CoV-2 antibody results. An appointment with the study GC will be scheduled to ensure informed decision-making and confirm patient preferences for secondary findings from WGS as well as serol. results. The GC appointment will be completed over the phone or teleconferencing software, depending on the patient's preference. Individuals with clin. actionable and/or rare genetic disease results will have their results returned to them by the study GC and/or clin. geneticist. Appropriate clin. referrals, as well as a plan for management and follow-up, will be established. If given permission, primary care providers will be notified of their patient's clin. actionable and/or rare genetic disease results. All other secondary findings (common conditions/disease risks, carrier status, and drug reactions) will be returned to patients through a study letter and genomic results report only. No clin. follow-up will be initiated by the research team. Significance: This study will highlight and present solutions to new challenges faced by GCs and other healthcare professionals when communicating serol. SARS-CoV-2 antibody and WGS results to an ostensibly healthy population. Addnl., this study will explore the feasibility of a remote workflow for intake, genetic counselling, and return of WGS results in the current medical landscape, potentially paving the way for the transition into alternative modes of healthcare delivery in the future.